TERESA ROSE-HELLEKANT

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. pmc Estrogen receptor-positive mammary tumorigenesis in TGFalpha transgenic mice progresses with progesterone receptor loss
    T A Rose-Hellekant
    Department of Pathobiological Sciences, University of Wisconsin Madison, Madison, WI, USA
    Oncogene 26:5238-46. 2007
  2. pmc Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptor-positive/progesterone receptor-negative mammary tumors
    Teresa A Rose-Hellekant
    Department of Physiology and Pharmacology, University of Minnesota Medical School Duluth Campus, 1035 University Drive, Duluth, MN 55812, USA
    Cancer Prev Res (Phila) 2:496-502. 2009

Research Grants

  1. GENETIC AND HORMONAL MECHANISMS OF BREAST CANCER
    Teresa Rose Hellekant; Fiscal Year: 2002
  2. Modulation of a breast cancer pathway by pregnancy
    Teresa Rose Hellekant; Fiscal Year: 2005
  3. Precancerous Mammary Transcriptome in Mice after Estrog*
    Teresa Rose Hellekant; Fiscal Year: 2006
  4. Local Delivery of Breast Cancer Chemopreventives Using Mesenchymal Stem Cells
    Teresa Rose Hellekant; Fiscal Year: 2007

Collaborators

Detail Information

Publications2

  1. pmc Estrogen receptor-positive mammary tumorigenesis in TGFalpha transgenic mice progresses with progesterone receptor loss
    T A Rose-Hellekant
    Department of Pathobiological Sciences, University of Wisconsin Madison, Madison, WI, USA
    Oncogene 26:5238-46. 2007
    ..Resulting tumors resemble a clinical phenotype of ER+/PR-, and when combined with a heterozygous p53 genotype, ER-/PR-...
  2. pmc Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptor-positive/progesterone receptor-negative mammary tumors
    Teresa A Rose-Hellekant
    Department of Physiology and Pharmacology, University of Minnesota Medical School Duluth Campus, 1035 University Drive, Duluth, MN 55812, USA
    Cancer Prev Res (Phila) 2:496-502. 2009
    ..This study validates the utility of NRL-TGFalpha mice for (a) identifying candidate biomarkers of efficacious tamoxifen chemoprevention and (b) modeling the evolution of tamoxifen resistance...

Research Grants6

  1. GENETIC AND HORMONAL MECHANISMS OF BREAST CANCER
    Teresa Rose Hellekant; Fiscal Year: 2002
    ....
  2. Modulation of a breast cancer pathway by pregnancy
    Teresa Rose Hellekant; Fiscal Year: 2005
    ..This application has the following specific aims: Aim 1. Develop transgenic mice that permit manipulation of TGFa expression in mammary epithelium. Aim 2. Establish how prior pregnancy affects TGFa -induced mammary tumorigenesis. ..
  3. Precancerous Mammary Transcriptome in Mice after Estrog*
    Teresa Rose Hellekant; Fiscal Year: 2006
    ..Knowing more about cancer molecules will bring more preventive agents quickly to clinical trials. ..
  4. Local Delivery of Breast Cancer Chemopreventives Using Mesenchymal Stem Cells
    Teresa Rose Hellekant; Fiscal Year: 2007
    ..Aim 2. Measure the effect of administering ACE-MSC-IFN-TRAIL-td-Tomato versus ACE-MSC-td-Tomato marker gene control to NRL-TGFa mice on tumor latency, incidence, multiplicity and mammary cell turnover dynamics. ..